Clinical Trials Logo
  1. Home
  2. Morbidly Adherent Placenta
  3. NCT03416296
  4. Details
NCT03416296 Clinical Trial

Role of Ultrasound in Diagnosis of Placenta Previa and MAP

Morbidly Adherent Placenta Clinical Trial

Official title:
Evaluation of Role of Ultrasound TA,TV,TP in Diagnosis of Placenta Previa and MAP(Morbidly Adherent Placenta )

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03416296
Other study ID # placenta
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 15, 2018
Est. completion date December 20, 2019

Study information
Verified date September 2021
Source Aljazeera Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Placenta accreta occurs when the placental implantation is abnormal. The marked rise in incidence has been assumed the increasing prevalence of cesarean delivery in recent years.

Description:

The most accepted theory is that abnormal placentation . The most important risk factor for placenta accreta is placenta previa after a prior cesarean delivery. The first clinical manifestation of placenta accreta is usually severe , life-threatening hemorrhage. The recommended intervention of suspected placenta accreta is planned preterm cesarean hysterectomy with the placenta left in situ.

Recruitment information / eligibility
Status Completed
Enrollment 90
Est. completion date December 20, 2019
Est. primary completion date June 10, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 43 Years
Eligibility Inclusion Criteria: - pregnant ladies with previous cesarean sections - GA above 30 weeks Exclusion Criteria: - Primigravida patients - GA below 30 weeks

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Egypt Algazeerah Giza

Sponsors (3)
Lead Sponsor Collaborator
Aljazeera Hospital Cairo University, National Research Centre, Egypt

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary number of participants who will be diagnosed to have normal placenta or placenta previa or morbidly adherent placenta by US within 6 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05817448 - Hypoxia-induced Autophagy in the Pathogenesis of MAP
Active, not recruiting NCT02784886 - Cell-free Fetal DNA Circulating in the Maternal Plasma as a Marker for Morbidly Adherent Placenta N/A
Recruiting NCT03676855 - Comparison Between Bladder Dissection Before and After Uterine Incision in Cesarean Section for Morbidly Adherent Placenta N/A
Withdrawn NCT02635412 - Delivery Timing in Morbidly Adherent Placentas: a Randomized, Controlled Trial N/A
Recruiting NCT04938050 - Diagnostic Accuracy of a Specialized Pro Forma in Assessing Morbidly Adherent Placenta With Correlation to Intra-operative Findings
Completed NCT03976453 - Psychological Outcome of Women With Morbidly Adherent Placenta Following Hystrectomy
Recruiting NCT05307016 - Morbidly Adherent Placenta, Diagnosis and Proper Management